- Home
- WTI vs LXEO Comparison
WTI vs LXEO Comparison
Compare WTI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTI
- LXEO
- Stock Information
- Founded
- WTI 1983
- LXEO 2017
- Country
- WTI United States
- LXEO United States
- Employees
- WTI N/A
- LXEO N/A
- Industry
- WTI Oil & Gas Production
- LXEO
- Sector
- WTI Energy
- LXEO
- Exchange
- WTI Nasdaq
- LXEO Nasdaq
- Market Cap
- WTI 259.9M
- LXEO 257.0M
- IPO Year
- WTI 2005
- LXEO 2023
- Fundamental
- Price
- WTI $1.76
- LXEO $4.79
- Analyst Decision
- WTI
- LXEO Strong Buy
- Analyst Count
- WTI 0
- LXEO 6
- Target Price
- WTI N/A
- LXEO $17.17
- AVG Volume (30 Days)
- WTI 1.4M
- LXEO 398.4K
- Earning Date
- WTI 08-04-2025
- LXEO 08-14-2025
- Dividend Yield
- WTI 2.28%
- LXEO N/A
- EPS Growth
- WTI N/A
- LXEO N/A
- EPS
- WTI N/A
- LXEO N/A
- Revenue
- WTI $493,951,000.00
- LXEO N/A
- Revenue This Year
- WTI $4.15
- LXEO N/A
- Revenue Next Year
- WTI $2.44
- LXEO N/A
- P/E Ratio
- WTI N/A
- LXEO N/A
- Revenue Growth
- WTI N/A
- LXEO N/A
- 52 Week Low
- WTI $1.09
- LXEO $1.45
- 52 Week High
- WTI $2.84
- LXEO $12.76
- Technical
- Relative Strength Index (RSI)
- WTI 48.61
- LXEO 59.85
- Support Level
- WTI $1.65
- LXEO $4.34
- Resistance Level
- WTI $1.79
- LXEO $4.96
- Average True Range (ATR)
- WTI 0.08
- LXEO 0.36
- MACD
- WTI -0.00
- LXEO 0.01
- Stochastic Oscillator
- WTI 36.96
- LXEO 76.59
About WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.